<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04433468</url>
  </required_header>
  <id_info>
    <org_study_id>2020RIPC</org_study_id>
    <nct_id>NCT04433468</nct_id>
  </id_info>
  <brief_title>Study on the Protective Effect of RIPC in Patients Undergoing Cardiac Surgery.</brief_title>
  <official_title>Study on the Protective Effect of RIPC in Patients Undergoing Cardiac Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the effect of RIPC on the function of vital organs after cardiac surgery, and to
      explore its possible mechanism.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of acute renal injury after operation</measure>
    <time_frame>within 7 days after operation</time_frame>
    <description>According to the (KDIGO) guidelines for improving the prognosis of renal disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of postoperative delirium</measure>
    <time_frame>within 7 days after operation</time_frame>
    <description>CAM score greater than 22</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>RIPC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RIPC</intervention_name>
    <description>The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.</description>
    <arm_group_label>RIPC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with aortic valve, mitral valve, tricuspid valve, ascending aortic disease
             and coronary atherosclerosis who were admitted to hospital for elective valve repair,
             replacement, artificial vascular replacement or coronary artery bypass grafting.

          -  age 18-80 years old.

          -  No restriction on gender.

          -  ASA grade II~III.

          -  NYHAII~III level.

          -  the patient or his family member has signed the informed consent form for the clinical
             trial

        Exclusion Criteria:

          -  those who are disabled in the selected test.

          -  less than 5 years of education.

          -  The preoperative left ventricular ejection fraction ((LVEF)) was less than 40%.

          -  Myocardial infarction occurred in nearly one month.

          -  malignant tumor, hematological disease, severe liver and kidney dysfunction, recent
             severe infection, etc.

          -  History of nervous system, immune system and mental illness.

          -  recent operation history of heart, brain, lung, liver, kidney and other important
             organs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

